George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 Apr 11. doi: 10.1007/s41669-024-00483-w
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Fleming AD, Mellor J, Jiang W, Storkey A, Styles CJ, McKeigue PM, Colhoun HM. Safe and efficient 2-year screening intervals allocated by manual and automated grading in nationwide diabetic retinopathy screening. Poster presented at the 58th EASD Annual Meeting; September 19, 2022. Stockholm, Sweden. [abstract] Diabetologia. 2022 Aug 3; 65(supplement 1):372. doi: 10.1007/s00125-022-05755-w
Mellor J, Jiang W, Fleming AD, Styles CJ, Storkey A, McKeigue PM, Colhoun HM, Scottish Diabetes Research Network. Evaluation of deep learning prediction models for cardiovascular risk prediction using fundus images from the Scottish Diabetic Retinopathy Screening programme. Poster presented at the 58th EASD Annual Meeting of the European Association for the Study of Diabetes; September 19, 2022. Stockholm, Sweden. [abstract] Diabetologia. 2022 Aug 3; 65(Supple 1):S408-9. doi: 10.1007/s00125-022-05755-w
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Berria R, Rosenstock J, Silberman C, Davis KL, Horton ES. Weight loss and associated changes in glycaemic control and cardiovascular biomarkers in patients with type 2 diabetes mellitus receiving incretin therapies in a large cohort database. Poster presented at the 44th General Assembly of the European Association for the Study of Diabetes; September 2009. [abstract] Diabetologia. 2009 Sep; 52(Suppl. 1, Abst.755):S297.
Küçükdeveci AA, McKenna SP, Kutlay S, Gürsel Y, Whalley D, Arasýl T. The development and psychometric assessment of the Turkish version of the Nottingham Health Profile. Int J Rehabil Res. 2000 Mar 1;23(1):31-8.